Pilot Study of Lapatinib (Tyverb) in Neoadjuvant Treatment for Patients With Locally Bladder Carcinoma Before Cystectomy.
Phase of Trial: Phase 0
Latest Information Update: 10 Jan 2013
At a glance
- Drugs Lapatinib (Primary)
- Indications Bladder cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms LAPAINBLAD
- 07 Jun 2017 Biomarkers information updated
- 13 Jun 2012 Additional lead trial investigators (Thierry Lebret and Pascal Rischmann) identified as reported by ClinicalTrials.gov.
- 13 Jun 2012 Planned end date changed from 1 Jan 2012 to 1 May 2013 as reported by ClinicalTrials.gov.